Search | Clinical Trials Finder

Conditions: Social Anxiety Disorder
Interventions: Low dose RLS103, High dose RLS103, placebo inhaled dry powder; Drug
Lead sponsor: Receptor Life Sciences; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Los Angeles, California • Oceanside, California • Torrance, California

Conditions: Diabetes Mellitus, Upper Respiratory Infection
Interventions: Technosphere Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Tuscon, Arizona • Fresno, California • Huntington Beach, California + 12 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 17
States / cities: San Mateo, California • Santa Barbara, California • Middlebury, Connecticut + 12 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Technosphere Insulin, Metformin & Secretagogues, Technosphere Insulin & Metformin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 25 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol); Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Healthy Volunteers
Interventions: Technosphere® Insulin 10U + 20U, Technosphere® Insulin 30U; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Healthy Volunteers
Interventions: TI-Inhalation Powder A, TI-Inhalation Powder B; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Subjects
Interventions: Technosphere Inhalation Powder (FDKP), Moxifloxacin, Placebo; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Diabetes Mellitus: Type 1
Interventions: Technosphere Insulin® Inhalation Powder, RAA Population; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 2
States / cities: Chula Vista, California • San Antonio, Texas

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Technosphere Insulin Inhalation Powder, Comparator; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 109
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 77 more

Conditions: Healthy Subjects
Interventions: TI Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetes, Type 1, Diabetes, Type 2
Interventions: Technosphere® Insulin Inhalation Powder, Usual Care; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 2,053 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 82
States / cities: Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 64 more

Conditions: Mild Nephropathy, Moderate Nephropathy, Diabetes Mellitus
Interventions: Technosphere Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Omaha, Nebraska • San Antonio, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Afrezza; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Afrezza, insulin degludec, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 19
States / cities: Loma Linda, California • Santa Barbara, California • Aurora, Colorado + 15 more

Conditions: Diabetes Type 2
Interventions: Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin); Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 80
States / cities: Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more

Conditions: Healthy Volunteers
Interventions: Technosphere® Insulin Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Healthy
Interventions: Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 58
States / cities: Burlingame, California • Escondido, California • Huntington Beach, California + 50 more

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 39
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 35 more

Conditions: Diabetes, Type 1
Interventions: Technosphere Insulin, Insulin glargine, Insulin lispro; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 20
States / cities: Huntington Beach, California • La Jolla, California • San Mateo, California + 14 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Technosphere®/Insulin; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Technosphere Insulin Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 14
States / cities: Montgomery, Alabama • Miami, Florida • Orland Park, Illinois + 10 more

Conditions: Type 2 Diabetes
Interventions: Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 29
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 22 more

Search by objective public record fields.

Safety, Tolerability, and Efficacy of RLS103 in Subjects With Acute Anxiety Within Social Anxiety Disorder (SAD)

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake

Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge

Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers

A Study to Determine if Technosphere® Inhalation Powder (FDKP) Causes ECG Changes (QTc) Following the Medication's Inhaled Administration.

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

A 2-Month Safety Follow-Up Trial

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Single Dose, Single Administration Study of Technosphere Inhalation Powder in Diabetic Subjects With Mild or Moderate Kidney Disease Compared to Diabetic Subjects With Normal Kidney Function

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Pharmacokinetic Study in Healthy Volunteers

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Afrezza® INHALE-1 Study in Pediatrics

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler